Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study
Avelumab first-line maintenance (1LM) neflintw-r6mpw is approved for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who do not have disease progression after platinum-based chemotherapy (PBC).This retrospective study describes real-world treatment patterns and clinical outcomes in patients with la/mUC who initiated first